title: Anti-inflammatory and Anti-nociceptive Actions of Systemically or Locally Treated Adipose-Derived Mesenchymal Stem Cells in Experimental Inflammatory Model.
abstract: Cell-based therapies using mesenchymal stem cells provide hopeful results. Therefore, in this present study, possible anti-inflammatory and anti-nociceptive actions of locally or systemically treated adipose-derived mesenchymal stem cells (ADMSCs) investigated in experimental inflammation model. ADMSCs were isolated from a male Wistar rat under anesthesia, and then they were cultured and expanded for transplantation in all the experimental animals. Effects of intraperitoneal or intraplantar ADMSC treatments on the hallmarks of the inflammatory nociception, such as hyperalgesia, allodynia, edema, and several biochemical parameters were investigated using a well-established carrageenan (CG)-induced hindpaw inflammation model in male rats. Both local and systemic ADMSC treatment increased the latencies, thresholds, and the development of edema in a time-dependent manner. In addition, administration of ADMSC suppressed the increased level of interleukin (IL)-1β, IL-6, and nitric oxide (NO), but further enhanced that of IL-10. Locally treated ADMSC at inflammatory sites effectively suppressed the CG-induced inflammatory responses when compared to the intraperitoneal route of administration. Findings suggest that therapeutic potential of ADMSC can change depending on its route of administration. Local ADMSC treatments may suppress the development of inflammatory-nociception and edema by decreasing the production of pro-inflammatory cytokines and NO level and increasing the anti-inflammatory cytokine production at inflammatory sites.
authors.affiliation: Department of Biophysics, School of Medicine, Kahramanmaras Sutcu Imam University, 46050, Kahramanmaras, Turkey, tufanmert@yahoo.com.
authors.forename: Tufan
authors.initials: T
authors.lastname: Mert
authors.forename: Akif H
authors.initials: AH
authors.lastname: Kurt
authors.forename: Mahmut
authors.initials: M
authors.lastname: Arslan
authors.forename: Ahmet
authors.initials: A
authors.lastname: Çelik
authors.forename: Berin
authors.initials: B
authors.lastname: Tugtag
authors.forename: Aysenur
authors.initials: A
authors.lastname: Akkurt
mesh_terms: D000273:Adipose Tissue / Q000166:cytology; D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004487:Edema / Q000628:therapy; D006930:Hyperalgesia / Q000628:therapy*; D007249:Inflammation / Q000628:therapy; D018836:Inflammation Mediators / Q000627:therapeutic use; D016753:Interleukin-10 / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology; D009569:Nitric Oxide / Q000097:blood; D059225:Nociception / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; C000594089:IL1B protein, rat; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D016753:Interleukin-10; D009569:Nitric Oxide